ý | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
¨ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 59-1995548 | |
(State of Incorporation) | (I.R.S. Employer Identification number) | |
2200 Pennsylvania Avenue, N.W., Suite 800W Washington, D.C. | 20037-1701 | |
(Address of Principal Executive Offices) | (Zip Code) |
Large accelerated filer | ý | Accelerated filer | ¨ | |||
Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | ¨ |
Page | ||
PART I - | FINANCIAL INFORMATION | |
PART II - | OTHER INFORMATION | |
July 3, 2015 | December 31, 2014 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and equivalents | $ | 3,342.0 | $ | 3,005.6 | |||
Trade accounts receivable, net | 3,565.2 | 3,633.8 | |||||
Inventories: | |||||||
Finished goods | 978.8 | 932.8 | |||||
Work in process | 260.6 | 276.6 | |||||
Raw materials | 672.8 | 622.1 | |||||
Total inventories | 1,912.2 | 1,831.5 | |||||
Prepaid expenses and other current assets | 835.1 | 960.4 | |||||
Total current assets | 9,654.5 | 9,431.3 | |||||
Property, plant and equipment, net of accumulated depreciation of $2,679.5 and $2,594.1, respectively | 2,161.3 | 2,203.0 | |||||
Other assets | 1,138.6 | 1,024.0 | |||||
Goodwill | 16,935.1 | 16,964.2 | |||||
Other intangible assets, net | 7,097.3 | 7,369.2 | |||||
Total assets | $ | 36,986.8 | $ | 36,991.7 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Notes payable and current portion of long-term debt | $ | 110.1 | $ | 71.9 | |||
Trade accounts payable | 1,744.1 | 1,875.0 | |||||
Accrued expenses and other liabilities | 3,201.4 | 3,449.5 | |||||
Total current liabilities | 5,055.6 | 5,396.4 | |||||
Other long-term liabilities | 4,706.5 | 4,744.0 | |||||
Long-term debt | 3,052.7 | 3,401.5 | |||||
Stockholders’ equity: | |||||||
Common stock - $0.01 par value | 8.0 | 7.9 | |||||
Additional paid-in capital | 4,728.1 | 4,480.9 | |||||
Retained earnings | 21,397.2 | 20,323.0 | |||||
Accumulated other comprehensive income (loss) | (2,032.1 | ) | (1,433.7 | ) | |||
Total Danaher stockholders’ equity | 24,101.2 | 23,378.1 | |||||
Non-controlling interests | 70.8 | 71.7 | |||||
Total stockholders’ equity | 24,172.0 | 23,449.8 | |||||
Total liabilities and stockholders’ equity | $ | 36,986.8 | $ | 36,991.7 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Sales | $ | 5,127.1 | $ | 4,963.6 | $ | 10,000.4 | $ | 9,626.3 | |||||||
Cost of sales | (2,366.9 | ) | (2,343.4 | ) | (4,640.2 | ) | (4,553.2 | ) | |||||||
Gross profit | 2,760.2 | 2,620.2 | 5,360.2 | 5,073.1 | |||||||||||
Operating costs: | |||||||||||||||
Selling, general and administrative expenses | (1,484.2 | ) | (1,394.5 | ) | (2,970.9 | ) | (2,745.1 | ) | |||||||
Research and development expenses | (344.9 | ) | (336.4 | ) | (684.0 | ) | (649.8 | ) | |||||||
Operating profit | 931.1 | 889.3 | 1,705.3 | 1,678.2 | |||||||||||
Non-operating income (expense): | |||||||||||||||
Other income | — | 19.2 | — | 19.2 | |||||||||||
Interest expense | (29.8 | ) | (33.2 | ) | (60.0 | ) | (65.7 | ) | |||||||
Interest income | 2.3 | 3.7 | 4.6 | 8.6 | |||||||||||
Earnings before income taxes | 903.6 | 879.0 | 1,649.9 | 1,640.3 | |||||||||||
Income taxes | (208.0 | ) | (202.6 | ) | (384.5 | ) | (384.2 | ) | |||||||
Net earnings | $ | 695.6 | $ | 676.4 | $ | 1,265.4 | $ | 1,256.1 | |||||||
Net earnings per share: | |||||||||||||||
Basic | $ | 0.98 | $ | 0.96 | $ | 1.79 | $ | 1.79 | |||||||
Diluted | $ | 0.97 | $ | 0.95 | $ | 1.76 | $ | 1.76 | |||||||
Average common stock and common equivalent shares outstanding: | |||||||||||||||
Basic | 709.5 | 701.2 | 708.4 | 700.6 | |||||||||||
Diluted | 719.6 | 715.6 | 719.2 | 715.2 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Net earnings | $ | 695.6 | $ | 676.4 | $ | 1,265.4 | $ | 1,256.1 | |||||||
Other comprehensive income (loss), net of income taxes: | |||||||||||||||
Foreign currency translation adjustments | 44.8 | 59.1 | (635.0 | ) | 51.9 | ||||||||||
Pension and post-retirement plan benefit adjustments | 7.1 | 3.5 | 14.1 | 2.5 | |||||||||||
Unrealized gain on available-for-sale securities | 23.9 | 24.6 | 22.5 | 36.9 | |||||||||||
Total other comprehensive income (loss), net of income taxes | 75.8 | 87.2 | (598.4 | ) | 91.3 | ||||||||||
Comprehensive income | $ | 771.4 | $ | 763.6 | $ | 667.0 | $ | 1,347.4 |
Common Stock | Additional Paid-in Capital | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non- Controlling Interests | ||||||||||||||||||
Shares | Amount | |||||||||||||||||||||
Balance, December 31, 2014 | 792.5 | $ | 7.9 | $ | 4,480.9 | $ | 20,323.0 | $ | (1,433.7 | ) | $ | 71.7 | ||||||||||
Net earnings for the period | — | — | — | 1,265.4 | — | — | ||||||||||||||||
Other comprehensive loss | — | — | — | — | (598.4 | ) | — | |||||||||||||||
Dividends declared | — | — | — | (191.2 | ) | — | — | |||||||||||||||
Common stock-based award activity | 3.8 | 0.1 | 197.9 | — | — | — | ||||||||||||||||
Common stock issued in connection with LYONs’ conversions, including tax benefit of $14.4 | 1.2 | — | 49.3 | — | — | — | ||||||||||||||||
Change in non-controlling interests | — | — | — | — | — | (0.9 | ) | |||||||||||||||
Balance, July 3, 2015 | 797.5 | $ | 8.0 | $ | 4,728.1 | $ | 21,397.2 | $ | (2,032.1 | ) | $ | 70.8 |
Six Months Ended | |||||||
July 3, 2015 | June 27, 2014 | ||||||
Cash flows from operating activities: | |||||||
Net earnings | $ | 1,265.4 | $ | 1,256.1 | |||
Non-cash items: | |||||||
Depreciation | 279.7 | 272.6 | |||||
Amortization | 216.0 | 187.5 | |||||
Stock-based compensation expense | 60.8 | 55.0 | |||||
Pre-tax gain on sales of investments | — | (19.2 | ) | ||||
Change in trade accounts receivable, net | 44.7 | (158.7 | ) | ||||
Change in inventories | (108.5 | ) | (58.8 | ) | |||
Change in trade accounts payable | (101.8 | ) | (51.0 | ) | |||
Change in prepaid expenses and other assets | 101.0 | 81.4 | |||||
Change in accrued expenses and other liabilities | (139.7 | ) | (62.0 | ) | |||
Net cash provided by operating activities | 1,617.6 | 1,502.9 | |||||
Cash flows from investing activities: | |||||||
Cash paid for acquisitions | (598.9 | ) | (606.7 | ) | |||
Payments for additions to property, plant and equipment | (258.1 | ) | (278.6 | ) | |||
Payments for purchases of investments | (87.1 | ) | — | ||||
Proceeds from sales of investments | — | 25.0 | |||||
All other investing activities | 6.5 | 11.2 | |||||
Net cash used in investing activities | (937.6 | ) | (849.1 | ) | |||
Cash flows from financing activities: | |||||||
Proceeds from the issuance of common stock | 131.5 | 60.9 | |||||
Payment of dividends | (165.9 | ) | (87.4 | ) | |||
Net repayments of borrowings (maturities of 90 days or less) | (259.9 | ) | (13.4 | ) | |||
Repayments of borrowings (maturities longer than 90 days) | (1.8 | ) | (403.6 | ) | |||
All other financing activities | (3.3 | ) | — | ||||
Net cash used in financing activities | (299.4 | ) | (443.5 | ) | |||
Effect of exchange rate changes on cash and equivalents | (44.2 | ) | (4.4 | ) | |||
Net change in cash and equivalents | 336.4 | 205.9 | |||||
Beginning balance of cash and equivalents | 3,005.6 | 3,115.2 | |||||
Ending balance of cash and equivalents | $ | 3,342.0 | $ | 3,321.1 | |||
Supplemental disclosures: | |||||||
Cash interest payments | $ | 57.7 | $ | 60.3 | |||
Cash income tax payments | $ | 225.1 | $ | 238.3 |
Foreign Currency Translation Adjustments | Pension and Post-Retirement Plan Benefit Adjustments | Unrealized Gain on Available-For- Sale Securities | Total | ||||||||||||
For the Three Months Ended July 3, 2015: | |||||||||||||||
Balance, April 3, 2015 | $ | (1,501.6 | ) | $ | (720.8 | ) | $ | 114.5 | $ | (2,107.9 | ) | ||||
Other comprehensive income (loss) before reclassifications: | |||||||||||||||
Increase | 44.8 | — | 38.3 | 83.1 | |||||||||||
Income tax impact | — | — | (14.4 | ) | (14.4 | ) | |||||||||
Other comprehensive income (loss) before reclassifications, net of income taxes | 44.8 | — | 23.9 | 68.7 | |||||||||||
Amounts reclassified from accumulated other comprehensive income (loss): | |||||||||||||||
Increase | — | 10.4 | (1) | — | 10.4 | ||||||||||
Income tax impact | — | (3.3 | ) | — | (3.3 | ) | |||||||||
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | — | 7.1 | — | 7.1 | |||||||||||
Net current period other comprehensive income (loss), net of income taxes | 44.8 | 7.1 | 23.9 | 75.8 | |||||||||||
Balance, July 3, 2015 | $ | (1,456.8 | ) | $ | (713.7 | ) | $ | 138.4 | $ | (2,032.1 | ) | ||||
(1) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost (refer to Note 7 for additional details). |
Foreign Currency Translation Adjustments | Pension and Post-Retirement Plan Benefit Adjustments | Unrealized Gain on Available-For- Sale Securities | Total | ||||||||||||
For the Three Months Ended June 27, 2014: | |||||||||||||||
Balance, March 28, 2014 | $ | 406.0 | $ | (367.7 | ) | $ | 180.3 | $ | 218.6 | ||||||
Other comprehensive income (loss) before reclassifications: | |||||||||||||||
Increase | 59.1 | — | 58.7 | 117.8 | |||||||||||
Income tax impact | — | — | (22.1 | ) | (22.1 | ) | |||||||||
Other comprehensive income (loss) before reclassifications, net of income taxes | 59.1 | — | 36.6 | 95.7 | |||||||||||
Amounts reclassified from accumulated other comprehensive income (loss): | |||||||||||||||
Increase (decrease) | — | 5.4 | (1) | (19.2 | ) | (2) | (13.8 | ) | |||||||
Income tax impact | — | (1.9 | ) | 7.2 | 5.3 | ||||||||||
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | — | 3.5 | (12.0 | ) | (8.5 | ) | |||||||||
Net current period other comprehensive income (loss), net of income taxes | 59.1 | 3.5 | 24.6 | 87.2 | |||||||||||
Balance, June 27, 2014 | $ | 465.1 | $ | (364.2 | ) | $ | 204.9 | $ | 305.8 | ||||||
For the Six Months Ended July 3, 2015: | |||||||||||||||
Balance, December 31, 2014 | $ | (821.8 | ) | $ | (727.8 | ) | $ | 115.9 | $ | (1,433.7 | ) | ||||
Other comprehensive income (loss) before reclassifications: | |||||||||||||||
(Decrease) increase | (635.0 | ) | — | 36.0 | (599.0 | ) | |||||||||
Income tax impact | — | — | (13.5 | ) | (13.5 | ) | |||||||||
Other comprehensive income (loss) before reclassifications, net of income taxes | (635.0 | ) | — | 22.5 | (612.5 | ) | |||||||||
Amounts reclassified from accumulated other comprehensive income (loss): | |||||||||||||||
Increase | — | 20.7 | (1) | — | 20.7 | ||||||||||
Income tax impact | — | (6.6 | ) | — | (6.6 | ) | |||||||||
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | — | 14.1 | — | 14.1 | |||||||||||
Net current period other comprehensive income (loss), net of income taxes | (635.0 | ) | 14.1 | 22.5 | (598.4 | ) | |||||||||
Balance, July 3, 2015 | $ | (1,456.8 | ) | $ | (713.7 | ) | $ | 138.4 | $ | (2,032.1 | ) | ||||
For the Six Months Ended June 27, 2014: | |||||||||||||||
Balance, December 31, 2013 | $ | 413.2 | $ | (366.7 | ) | $ | 168.0 | $ | 214.5 | ||||||
Other comprehensive income (loss) before reclassifications: | |||||||||||||||
Increase (decrease) | 51.9 | (5.5 | ) | 78.3 | 124.7 | ||||||||||
Income tax impact | — | 1.1 | (29.4 | ) | (28.3 | ) | |||||||||
Other comprehensive income (loss) before reclassifications, net of income taxes | 51.9 | (4.4 | ) | 48.9 | 96.4 | ||||||||||
Amounts reclassified from accumulated other comprehensive income (loss): | |||||||||||||||
Increase (decrease) | — | 10.7 | (1) | (19.2 | ) | (2) | (8.5 | ) | |||||||
Income tax impact | — | (3.8 | ) | 7.2 | 3.4 | ||||||||||
Amounts reclassified from accumulated other comprehensive income (loss), net of income taxes | — | 6.9 | (12.0 | ) | (5.1 | ) | |||||||||
Net current period other comprehensive income (loss), net of income taxes | 51.9 | 2.5 | 36.9 | 91.3 | |||||||||||
Balance, June 27, 2014 | $ | 465.1 | $ | (364.2 | ) | $ | 204.9 | $ | 305.8 | ||||||
(1) This accumulated other comprehensive income (loss) component is included in the computation of net periodic pension cost (refer to Note 7 for additional details). (2) Included in other income in the accompanying Consolidated Condensed Statement of Earnings. |
Trade accounts receivable | $ | 55.3 | |
Inventories | 26.4 | ||
Property, plant and equipment | 20.6 | ||
Goodwill | 269.3 | ||
Other intangible assets, primarily customer relationships, trade names and technology | 205.8 | ||
Trade accounts payable | (11.4 | ) | |
Other assets and liabilities, net | 32.9 | ||
Net cash consideration | $ | 598.9 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Sales | $ | 5,132.9 | $ | 5,317.8 | $ | 10,042.7 | $ | 10,348.0 | |||||||
Net earnings | 695.5 | 691.2 | 1,279.5 | 1,267.8 | |||||||||||
Diluted net earnings per share | 0.97 | 0.97 | 1.78 | 1.78 |
• | a science and technology growth company (“New Danaher”). This company will retain the Danaher name and will include businesses that generated approximately $16.5 billion in revenues (adjusted to include the revenues of Pall - refer to Note 2), in their most recently completed fiscal year; and |
• | a diversified industrial growth company (“NewCo”). The businesses expected to comprise NewCo generated approximately $6.0 billion in revenues in their most recently completed fiscal year. |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Sales | $ | 167.1 | $ | 180.1 | $ | 345.7 | $ | 403.6 | |||||||
Operating profit | (3.1 | ) | 13.7 | 16.0 | 64.6 |
Balance, December 31, 2014 | $ | 16,964.2 | |
Attributable to 2015 acquisitions | 269.3 | ||
Foreign currency translation & other | (298.4 | ) | |
Balance, July 3, 2015 | $ | 16,935.1 |
July 3, 2015 | December 31, 2014 | ||||||
Test & Measurement | $ | 3,203.7 | $ | 3,238.4 | |||
Environmental | 1,953.4 | 1,937.3 | |||||
Life Sciences & Diagnostics | 6,394.1 | 6,345.2 | |||||
Dental | 3,127.3 | 3,142.9 | |||||
Industrial Technologies | 2,256.6 | 2,300.4 | |||||
Total goodwill | $ | 16,935.1 | $ | 16,964.2 |
Quoted Prices in Active Market (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | |||||||||||
July 3, 2015: | ||||||||||||||
Assets: | ||||||||||||||
Available-for-sale securities | $ | 380.6 | — | — | $ | 380.6 | ||||||||
Liabilities: | ||||||||||||||
Deferred compensation plans | — | $ | 76.3 | — | 76.3 | |||||||||
December 31, 2014: | ||||||||||||||
Assets: | ||||||||||||||
Available-for-sale securities | $ | 257.5 | — | — | $ | 257.5 | ||||||||
Liabilities: | ||||||||||||||
Deferred compensation plans | — | $ | 75.0 | — | 75.0 |
July 3, 2015 | December 31, 2014 | ||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | ||||||||||||
Assets: | |||||||||||||||
Available-for-sale securities | $ | 380.6 | $ | 380.6 | $ | 257.5 | $ | 257.5 | |||||||
Liabilities: | |||||||||||||||
Short-term borrowings | 110.1 | 110.1 | 71.9 | 71.9 | |||||||||||
Long-term borrowings | 3,052.7 | 3,380.0 | 3,401.5 | 3,809.1 |
July 3, 2015 | December 31, 2014 | ||||||
Commercial paper | $ | 450.0 | $ | 764.6 | |||
2.3% senior unsecured notes due 2016 | 500.0 | 500.0 | |||||
5.625% senior unsecured notes due 2018 | 500.0 | 500.0 | |||||
5.4% senior unsecured notes due 2019 | 750.0 | 750.0 | |||||
3.9% senior unsecured notes due 2021 | 600.0 | 600.0 | |||||
4.0% bonds due 2016 (CHF 120.0 million aggregate principal amount) | 135.7 | 129.9 | |||||
Zero-coupon LYONs due 2021 | 76.7 | 110.6 | |||||
Other | 150.4 | 118.3 | |||||
Subtotal | 3,162.8 | 3,473.4 | |||||
Less currently payable | 110.1 | 71.9 | |||||
Long-term debt | $ | 3,052.7 | $ | 3,401.5 |
• | €500 million aggregate principal amount of floating rate senior notes due 2017 (the “2017 Euronotes”). The 2017 Euronotes were issued at 100% of their principal amount, will mature on June 30, 2017 and bear interest at a floating rate equal to three-month EURIBOR plus 0.45% per year. |
• | €600 million aggregate principal amount of 1.0% senior notes due 2019 (the “2019 Euronotes”). The 2019 Euronotes were issued at 99.696% of their principal amount, will mature on July 8, 2019 and bear interest at the rate of 1.0% per year. |
• | €800 million aggregate principal amount of 1.7% senior notes due 2022 (the “2022 Euronotes”). The 2022 Euronotes were issued at 99.651% of their principal amount, will mature on January 4, 2022 and bear interest at the rate of 1.7% per year. |
• | €800 million aggregate principal amount of 2.5% senior notes due 2025 (the “2025 Euronotes”). The 2025 Euronotes were issued at 99.878% of their principal amount, will mature on July 8, 2025 and bear interest at the rate of 2.5% per year. |
• | on the floating rate 2017 Euronotes quarterly in arrears on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2015; |
• | on the 2019 Euronotes and 2025 Euronotes annually in arrears on July 8 of each year, commencing on July 8, 2016; and |
• | on the 2022 Euronotes annually in arrears on January 4 of each year, commencing on January 4, 2016. |
U.S. Pension Benefits | |||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Service cost | $ | 1.5 | $ | 1.5 | $ | 3.0 | $ | 3.0 | |||||||
Interest cost | 24.5 | 26.5 | 48.6 | 53.0 | |||||||||||
Expected return on plan assets | (33.4 | ) | (32.3 | ) | (66.2 | ) | (64.6 | ) | |||||||
Amortization of actuarial loss | 6.5 | 4.6 | 13.0 | 9.2 | |||||||||||
Net periodic pension cost | $ | (0.9 | ) | $ | 0.3 | $ | (1.6 | ) | $ | 0.6 | |||||
Non-U.S. Pension Benefits | |||||||||||||||
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Service cost | $ | 11.3 | $ | 8.0 | $ | 22.7 | $ | 16.0 | |||||||
Interest cost | 8.6 | 11.8 | 17.3 | 23.5 | |||||||||||
Expected return on plan assets | (9.5 | ) | (10.6 | ) | (19.0 | ) | (21.1 | ) | |||||||
Amortization of actuarial loss | 4.1 | 1.8 | 8.5 | 3.5 | |||||||||||
Amortization of prior service credit | — | — | (0.1 | ) | — | ||||||||||
Settlement gain recognized | (0.1 | ) | — | (0.5 | ) | — | |||||||||
Net periodic pension cost | $ | 14.4 | $ | 11.0 | $ | 28.9 | $ | 21.9 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Service cost | $ | 0.3 | $ | 0.3 | $ | 0.6 | $ | 0.6 | |||||||
Interest cost | 2.0 | 2.1 | 4.0 | 4.2 | |||||||||||
Amortization of actuarial loss | 0.7 | — | 1.4 | — | |||||||||||
Amortization of prior service credit | (0.8 | ) | (1.0 | ) | (1.6 | ) | (2.0 | ) | |||||||
Net periodic benefit cost | $ | 2.2 | $ | 1.4 | $ | 4.4 | $ | 2.8 |
Risk-free interest rate | 1.6% - 1.9% | |
Weighted average volatility | 23.2 | % |
Dividend yield | 0.6 | % |
Expected years until exercise | 5.5 - 8.0 |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
RSUs/PSUs: | |||||||||||||||
Pre-tax compensation expense | $ | 18.7 | $ | 15.9 | $ | 38.1 | $ | 33.8 | |||||||
Income tax benefit | (6.5 | ) | (4.4 | ) | (12.4 | ) | (9.6 | ) | |||||||
RSU/PSU expense, net of income taxes | 12.2 | 11.5 | 25.7 | 24.2 | |||||||||||
Stock options: | |||||||||||||||
Pre-tax compensation expense | 10.7 | 10.1 | 22.7 | 21.2 | |||||||||||
Income tax benefit | (3.7 | ) | (2.9 | ) | (7.3 | ) | (6.3 | ) | |||||||
Stock option expense, net of income taxes | 7.0 | 7.2 | 15.4 | 14.9 | |||||||||||
Total stock-based compensation: | |||||||||||||||
Pre-tax compensation expense | 29.4 | 26.0 | 60.8 | 55.0 | |||||||||||
Income tax benefit | (10.2 | ) | (7.3 | ) | (19.7 | ) | (15.9 | ) | |||||||
Total stock-based compensation expense, net of income taxes | $ | 19.2 | $ | 18.7 | $ | 41.1 | $ | 39.1 |
Options | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term (in years) | Aggregate Intrinsic Value | |||||||||
Outstanding as of December 31, 2014 | 24.3 | $ | 48.92 | |||||||||
Granted | 1.3 | 86.99 | ||||||||||
Exercised | (3.1 | ) | 34.44 | |||||||||
Cancelled/forfeited | (0.8 | ) | 61.49 | |||||||||
Outstanding as of July 3, 2015 | 21.7 | $ | 52.82 | 6 | $ | 738.4 | ||||||
Vested and expected to vest as of July 3, 2015 (1) | 20.6 | $ | 52.00 | 6 | $ | 717.6 | ||||||
Vested as of July 3, 2015 | 11.3 | $ | 39.78 | 4 | $ | 533.1 |
Number of RSUs/PSUs | Weighted Average Grant-Date Fair Value | |||||
Unvested as of December 31, 2014 | 4.9 | $ | 61.64 | |||
Granted | 0.5 | 85.24 | ||||
Vested | (0.7 | ) | 57.38 | |||
Forfeited | (0.3 | ) | 65.70 | |||
Unvested as of July 3, 2015 | 4.4 | $ | 64.61 |
Balance, December 31, 2014 | $ | 139.1 | |
Accruals for warranties issued during the period | 58.2 | ||
Settlements made | (65.7 | ) | |
Additions due to acquisitions | 0.8 | ||
Effect of foreign currency translation | (2.0 | ) | |
Balance, July 3, 2015 | $ | 130.4 |
Net Earnings (Numerator) | Shares (Denominator) | Per Share Amount | ||||||||
For the Three Months Ended July 3, 2015: | ||||||||||
Basic EPS | $ | 695.6 | 709.5 | $ | 0.98 | |||||
Adjustment for interest on convertible debentures | 0.6 | — | ||||||||
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs | — | 7.5 | ||||||||
Incremental shares from assumed conversion of the convertible debentures | — | 2.6 | ||||||||
Diluted EPS | $ | 696.2 | 719.6 | $ | 0.97 |
For the Three Months Ended June 27, 2014: | ||||||||||
Basic EPS | $ | 676.4 | 701.2 | $ | 0.96 | |||||
Adjustment for interest on convertible debentures | 1.0 | — | ||||||||
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs | — | 9.2 | ||||||||
Incremental shares from assumed conversion of the convertible debentures | — | 5.2 | ||||||||
Diluted EPS | $ | 677.4 | 715.6 | $ | 0.95 |
Net Earnings (Numerator) | Shares (Denominator) | Per Share Amount | ||||||||
For the Six Months Ended July 3, 2015: | ||||||||||
Basic EPS | $ | 1,265.4 | 708.4 | $ | 1.79 | |||||
Adjustment for interest on convertible debentures | 1.2 | — | ||||||||
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs | — | 7.9 | ||||||||
Incremental shares from assumed conversion of the convertible debentures | — | 2.9 | ||||||||
Diluted EPS | $ | 1,266.6 | 719.2 | $ | 1.76 |
For the Six Months Ended June 27, 2014: | ||||||||||
Basic EPS | $ | 1,256.1 | 700.6 | $ | 1.79 | |||||
Adjustment for interest on convertible debentures | 1.7 | — | ||||||||
Incremental shares from assumed exercise of dilutive options and vesting of dilutive RSUs and PSUs | — | 9.4 | ||||||||
Incremental shares from assumed conversion of the convertible debentures | — | 5.2 | ||||||||
Diluted EPS | $ | 1,257.8 | 715.2 | $ | 1.76 |
Three Months Ended | Six Months Ended | ||||||||||||||
Sales: | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Test & Measurement | $ | 842.4 | $ | 856.5 | $ | 1,699.9 | $ | 1,727.5 | |||||||
Environmental | 892.3 | 876.0 | 1,715.5 | 1,644.7 | |||||||||||
Life Sciences & Diagnostics | 1,840.3 | 1,790.0 | 3,536.0 | 3,449.6 | |||||||||||
Dental | 687.6 | 528.1 | 1,350.0 | 1,037.8 | |||||||||||
Industrial Technologies | 864.5 | 913.0 | 1,699.0 | 1,766.7 | |||||||||||
Total | $ | 5,127.1 | $ | 4,963.6 | $ | 10,000.4 | $ | 9,626.3 | |||||||
Operating Profit: | |||||||||||||||
Test & Measurement | $ | 160.6 | $ | 157.8 | $ | 331.3 | $ | 350.5 | |||||||
Environmental | 201.1 | 183.8 | 361.7 | 329.4 | |||||||||||
Life Sciences & Diagnostics | 285.9 | 282.7 | 501.4 | 502.4 | |||||||||||
Dental | 97.3 | 77.9 | 157.4 | 153.4 | |||||||||||
Industrial Technologies | 221.4 | 217.5 | 426.6 | 409.2 | |||||||||||
Other | (35.2 | ) | (30.4 | ) | (73.1 | ) | (66.7 | ) | |||||||
Total | $ | 931.1 | $ | 889.3 | $ | 1,705.3 | $ | 1,678.2 |
• | Information Relating to Forward-Looking Statements |
• | Overview |
• | Results of Operations |
• | Liquidity and Capital Resources |
• | Conditions in the global economy, the markets we serve and the financial markets may adversely affect our business and financial statements. |
• | Our restructuring actions could have long-term adverse effects on our business. |
• | Our growth could suffer if the markets into which we sell our products (including software) and services decline, do not grow as anticipated or experience cyclicality. |
• | We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce prices for our products and services. |
• | Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation. |
• | Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents or business partners. |
• | Any inability to consummate acquisitions at our historical rate and at appropriate prices could negatively impact our growth rate and stock price. |
• | Our acquisition of businesses, joint ventures and strategic relationships could negatively impact our financial statements. |
• | Our anticipated acquisition of Pall Corporation may not be completed on the currently contemplated timeline, or at all, and if completed could negatively impact our financial position, profitability and return on invested capital. |
• | The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities. |
• | Divestitures and other dispositions could negatively impact our business, and contingent liabilities from businesses that we have sold could adversely affect our financial statements. |
• | We are pursuing a plan to separate into two independent publicly traded companies. The proposed separation may not be completed on the currently contemplated timeline, or at all, and may not achieve the intended benefits. |
• | Certain of our businesses are subject to extensive regulation by the U.S. Food and Drug Administration (“FDA”) and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our reputation and financial statements. |
• | The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce costs, which could adversely affect our financial statements. |
• | Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our reputation and financial statements. |
• | Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our financial statements and reputation. |
• | We may be required to recognize impairment charges for our goodwill and other intangible assets. |
• | Foreign currency exchange rates may adversely affect our financial statements. |
• | Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods. |
• | We are subject to a variety of litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our financial statements. |
• | If we do not or cannot adequately protect our intellectual property, or if third parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights. |
• | Third parties may claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services. |
• | Defects and unanticipated use or inadequate disclosure with respect to our products (including software) or services could adversely affect our business, reputation and financial statements. |
• | The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our reputation, business and financial statements could suffer. |
• | Our indebtedness may limit our operations and our use of our cash flow, and any failure to comply with the covenants that apply to our indebtedness could adversely affect our liquidity and financial statements. |
• | Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, key distributors and other channel partners could adversely affect our financial statements. |
• | Our financial results are subject to fluctuations in the cost and availability of commodities that we use in our operations. |
• | If we cannot adjust our manufacturing capacity or the purchases required for our manufacturing activities to reflect changes in market conditions and customer demand, our profitability may suffer. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services could cause production interruptions, delays and inefficiencies. |
• | Changes in governmental regulations may reduce demand for our products or services or increase our expenses. |
• | Work stoppages, union and works council campaigns and other labor disputes could adversely impact our productivity and results of operations. |
• | International economic, political, legal, compliance and business factors could negatively affect our financial statements. |
• | If we suffer loss to our facilities, supply chains, distribution systems or information technology systems due to catastrophe or other events, our operations could be seriously harmed. |
• | A significant disruption in, or breach in security of, our information technology systems could adversely affect our reputation and business. |
• | Our defined benefit pension plans are subject to financial market risks that could adversely affect our financial statements. |
• | a science and technology growth company (“New Danaher”). This company will retain the Danaher name and will include businesses that generated approximately $16.5 billion in revenues (adjusted to include the revenues of Pall - refer to Note 2 of the Consolidated Condensed Financial Statements), in their most recently completed fiscal year; and |
• | a diversified industrial growth company (“NewCo”). The businesses expected to comprise NewCo generated approximately $6.0 billion in revenues in their most recently completed fiscal year. |
• | Higher 2015 sales volumes and incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development, sales and marketing growth investments and the effect of a strong U.S. dollar - 80 basis points |
• | The incremental net dilutive effect in 2015 of acquired businesses and the product line disposition which occurred in the third quarter of 2014 - 50 basis points |
• | Higher 2015 sales volumes and incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development, sales and marketing growth investments and the continued effect of a strong U.S. dollar - 55 basis points |
• | The incremental net dilutive effect in 2015 of acquired businesses and the product line disposition which occurred in the third quarter of 2014 - 65 basis points |
• | Acquisition related charges associated with fair value adjustments to acquired inventory recorded in 2015 in connection with the Nobel Biocare acquisition (which acquisition occurred in December 2014) - 20 basis points |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Test & Measurement | $ | 842.4 | $ | 856.5 | $ | 1,699.9 | $ | 1,727.5 | |||||||
Environmental | 892.3 | 876.0 | 1,715.5 | 1,644.7 | |||||||||||
Life Sciences & Diagnostics | 1,840.3 | 1,790.0 | 3,536.0 | 3,449.6 | |||||||||||
Dental | 687.6 | 528.1 | 1,350.0 | 1,037.8 | |||||||||||
Industrial Technologies | 864.5 | 913.0 | 1,699.0 | 1,766.7 | |||||||||||
Total | $ | 5,127.1 | $ | 4,963.6 | $ | 10,000.4 | $ | 9,626.3 |
Three Months Ended | Six Months Ended | ||||||||||||||
($ in millions) | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Sales | $ | 842.4 | $ | 856.5 | $ | 1,699.9 | $ | 1,727.5 | |||||||
Operating profit | 160.6 | 157.8 | 331.3 | 350.5 | |||||||||||
Depreciation | 9.8 | 10.5 | 19.4 | 21.1 | |||||||||||
Amortization | 21.9 | 23.4 | 44.1 | 46.0 | |||||||||||
Operating profit as a % of sales | 19.1 | % | 18.4 | % | 19.5 | % | 20.3 | % | |||||||
Depreciation as a % of sales | 1.2 | % | 1.2 | % | 1.1 | % | 1.2 | % | |||||||
Amortization as a % of sales | 2.6 | % | 2.7 | % | 2.6 | % | 2.7 | % |
% Change Three Months Ended July 3, 2015 vs. Comparable 2014 Period | % Change Six Months Ended July 3, 2015 vs. Comparable 2014 Period | ||||
Existing businesses | 2.5 | % | 2.5 | % | |
Acquisitions | — | % | — | % | |
Currency exchange rates | (4.0 | )% | (4.0 | )% | |
Total | (1.5 | )% | (1.5 | )% |
Three Months Ended | Six Months Ended | ||||||||||||||
($ in millions) | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Sales | $ | 892.3 | $ | 876.0 | $ | 1,715.5 | $ | 1,644.7 | |||||||
Operating profit | 201.1 | 183.8 | 361.7 | 329.4 | |||||||||||
Depreciation | 14.1 | 14.2 | 26.9 | 24.2 | |||||||||||
Amortization | 9.1 | 8.8 | 18.1 | 16.8 | |||||||||||
Operating profit as a % of sales | 22.5 | % | 21.0 | % | 21.1 | % | 20.0 | % | |||||||
Depreciation as a % of sales | 1.6 | % | 1.6 | % | 1.6 | % | 1.5 | % | |||||||
Amortization as a % of sales | 1.0 | % | 1.0 | % | 1.1 | % | 1.0 | % |
% Change Three Months Ended July 3, 2015 vs. Comparable 2014 Period | % Change Six Months Ended July 3, 2015 vs. Comparable 2014 Period | ||||
Existing businesses | 3.0 | % | 5.5 | % | |
Acquisitions | 5.5 | % | 5.5 | % | |
Currency exchange rates | (6.5 | )% | (6.5 | )% | |
Total | 2.0 | % | 4.5 | % |
• | Higher 2015 sales volumes and incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development initiatives and the effect of a strong U.S. dollar - 145 basis points |
• | The incremental accretive effect in 2015 of acquired businesses - 5 basis points |
• | Higher 2015 sales volumes and incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development initiatives and the continued effect of a strengthening U.S. dollar - 160 basis points |
• | The incremental net dilutive effect in 2015 of acquired businesses - 50 basis points |
Three Months Ended | Six Months Ended | ||||||||||||||
($ in millions) | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Sales | $ | 1,840.3 | $ | 1,790.0 | $ | 3,536.0 | $ | 3,449.6 | |||||||
Operating profit | 285.9 | 282.7 | 501.4 | 502.4 | |||||||||||
Depreciation | 92.1 | 92.9 | 182.0 | 182.5 | |||||||||||
Amortization | 47.4 | 40.3 | 93.9 | 79.5 | |||||||||||
Operating profit as a % of sales | 15.5 | % | 15.8 | % | 14.2 | % | 14.6 | % | |||||||
Depreciation as a % of sales | 5.0 | % | 5.2 | % | 5.1 | % | 5.3 | % | |||||||
Amortization as a % of sales | 2.6 | % | 2.3 | % | 2.7 | % | 2.3 | % |
% Change Three Months Ended July 3, 2015 vs. Comparable 2014 Period | % Change Six Months Ended July 3, 2015 vs. Comparable 2014 Period | ||||
Existing businesses | 4.5 | % | 5.0 | % | |
Acquisitions | 5.5 | % | 5.0 | % | |
Currency exchange rates | (7.0 | )% | (7.5 | )% | |
Total | 3.0 | % | 2.5 | % |
• | Incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with sales and marketing growth investments and the effect of a strong U.S. dollar - 55 basis points |
• | The incremental net dilutive effect in 2015 of acquired businesses - 85 basis points |
• | Incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development and the continued effect of a strengthening U.S. dollar - 85 basis points |
• | The incremental net dilutive effect in 2015 of acquired businesses - 125 basis points |
Three Months Ended | Six Months Ended | ||||||||||||||
($ in millions) | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Sales | $ | 687.6 | $ | 528.1 | $ | 1,350.0 | $ | 1,037.8 | |||||||
Operating profit | 97.3 | 77.9 | 157.4 | 153.4 | |||||||||||
Depreciation | 12.3 | 8.9 | 25.0 | 17.6 | |||||||||||
Amortization | 19.4 | 11.6 | 41.5 | 23.4 | |||||||||||
Operating profit as a % of sales | 14.2 | % | 14.8 | % | 11.7 | % | 14.8 | % | |||||||
Depreciation as a % of sales | 1.8 | % | 1.7 | % | 1.9 | % | 1.7 | % | |||||||
Amortization as a % of sales | 2.8 | % | 2.2 | % | 3.1 | % | 2.3 | % |
% Change Three Months Ended July 3, 2015 vs. Comparable 2014 Period | % Change Six Months Ended July 3, 2015 vs. Comparable 2014 Period | ||||
Existing businesses | 1.0 | % | 0.5 | % | |
Acquisitions | 37.5 | % | 38.5 | % | |
Currency exchange rates | (8.5 | )% | (9.0 | )% | |
Total | 30.0 | % | 30.0 | % |
• | Incremental year-over-year costs associated with various product development, sales and marketing growth investments and the effect of a strong U.S. dollar, net of incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014 - 25 basis points |
• | The incremental net dilutive effect in 2015 of acquired businesses (as Nobel Biocare is integrated into the Company, the Company expects to realize significant cost synergies through the application of the Danaher Business System and the combined purchasing power of the Company and Nobel Biocare) - 35 basis points |
• | The incremental net accretive effect in 2015 of acquired businesses - 40 basis points |
• | Lower 2015 sales volumes from existing businesses and incremental year-over-year costs associated with various product development, sales and marketing growth investments and the continued effect of a strong U.S. dollar, net of incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014 - 200 basis points |
• | Acquisition related charges associated with fair value adjustments to acquired inventory recorded in 2015 in connection with the Nobel Biocare acquisition - 150 basis points |
Three Months Ended | Six Months Ended | ||||||||||||||
July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | ||||||||||||
Sales | $ | 864.5 | $ | 913.0 | $ | 1,699.0 | $ | 1,766.7 | |||||||
Operating profit | 221.4 | 217.5 | 426.6 | 409.2 | |||||||||||
Depreciation | 10.9 | 11.9 | 22.3 | 23.4 | |||||||||||
Amortization | 9.3 | 10.9 | 18.4 | 21.8 | |||||||||||
Operating profit as a % of sales | 25.6 | % | 23.8 | % | 25.1 | % | 23.2 | % | |||||||
Depreciation as a % of sales | 1.3 | % | 1.3 | % | 1.3 | % | 1.3 | % | |||||||
Amortization as a % of sales | 1.1 | % | 1.2 | % | 1.1 | % | 1.2 | % |
% Change Three Months Ended July 3, 2015 vs. Comparable 2014 Period | % Change Six Months Ended July 3, 2015 vs. Comparable 2014 Period | ||||
Existing businesses | 4.0 | % | 5.5 | % | |
Acquisitions (divestitures), net | (3.5 | )% | (3.5 | )% | |
Currency exchange rates | (6.0 | )% | (6.0 | )% | |
Total | (5.5 | )% | (4.0 | )% |
• | Higher 2015 sales volumes, incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development and sales and marketing growth investments - 165 basis points |
• | The incremental net accretive effect in 2015 of the product line disposition which occurred in the third quarter of 2014 - 15 basis points |
• | Higher 2015 sales volumes, incremental year-over-year cost savings associated with the restructuring actions and continuing productivity improvement initiatives taken in 2014, net of incremental year-over-year costs associated with various new product development and sales and marketing growth investments - 170 basis points |
• | The incremental net accretive effect in 2015 of the product line disposition which occurred in the third quarter of 2014 - 20 basis points |
Three Months Ended | Six Months Ended | ||||||||||||||
($ in millions) | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Sales | $ | 5,127.1 | $ | 4,963.6 | $ | 10,000.4 | $ | 9,626.3 | |||||||
Cost of sales | (2,366.9 | ) | (2,343.4 | ) | (4,640.2 | ) | (4,553.2 | ) | |||||||
Gross profit | 2,760.2 | 2,620.2 | 5,360.2 | 5,073.1 | |||||||||||
Gross profit margin | 53.8 | % | 52.8 | % | 53.6 | % | 52.7 | % |
Three Months Ended | Six Months Ended | ||||||||||||||
($ in millions) | July 3, 2015 | June 27, 2014 | July 3, 2015 | June 27, 2014 | |||||||||||
Sales | $ | 5,127.1 | $ | 4,963.6 | $ | 10,000.4 | $ | 9,626.3 | |||||||
Selling, general and administrative ("SG&A") expenses | 1,484.2 | 1,394.5 | 2,970.9 | 2,745.1 | |||||||||||
Research and development ("R&D") expenses | 344.9 | 336.4 | 684.0 | 649.8 | |||||||||||
SG&A as a % of sales | 28.9 | % | 28.1 | % | 29.7 | % | 28.5 | % | |||||||
R&D as a % of sales | 6.7 | % | 6.8 | % | 6.8 | % | 6.8 | % |
Six Months Ended | |||||||
($ in millions) | July 3, 2015 | June 27, 2014 | |||||
Total operating cash flows | $ | 1,617.6 | $ | 1,502.9 | |||
Cash paid for acquisitions | $ | (598.9 | ) | $ | (606.7 | ) | |
Payments for additions to property, plant and equipment | (258.1 | ) | (278.6 | ) | |||
Payments for purchases of investments | (87.1 | ) | — | ||||
Proceeds from sales of investments | — | 25.0 | |||||
All other investing activities | 6.5 | 11.2 | |||||
Net cash used in investing activities | $ | (937.6 | ) | $ | (849.1 | ) | |
Proceeds from the issuance of common stock | $ | 131.5 | $ | 60.9 | |||
Payment of dividends | (165.9 | ) | (87.4 | ) | |||
Repayments of borrowings (maturities of 90 days or less) | (259.9 | ) | (13.4 | ) | |||
Repayments of borrowings (maturities longer than 90 days) | (1.8 | ) | (403.6 | ) | |||
All other financing activities | (3.3 | ) | — | ||||
Net cash used in financing activities | $ | (299.4 | ) | $ | (443.5 | ) |
• | Operating cash flows increased $115 million during the first half of 2015 as compared to the first half of 2014, primarily due to higher operating profit as well as higher non-cash charges for depreciation, amortization and stock compensation, decreased income tax payments and lower levels of investment in working capital during 2015 compared to 2014. |
• | Cash paid for acquisitions constituted the most significant use of cash during the first half of 2015. The Company acquired seven businesses during the first half of 2015 for total consideration (net of cash acquired) of $599 million. |
• | As of July 3, 2015, the Company held approximately $3.3 billion of cash and cash equivalents. |
• | The aggregate of trade accounts receivable, inventories and trade accounts payable used $166 million in operating cash flows during the first half of 2015, compared to $269 million used in the comparable period of 2014. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories and trade accounts payable depends upon how effectively the Company manages the cash conversion cycle, which effectively represents the number of days that elapse from the day it pays for the purchase of raw materials and components to the collection of cash from its customers and can be significantly impacted by the timing of collections and payments in a period. |
• | The aggregate of prepaid expenses and other assets and accrued expenses and other liabilities used $39 million of operating cash during the first half of 2015, compared to $19 million provided in the comparable period of 2014. The increase in deferred revenue offset by the timing of cash payments for income taxes as well as payments of various employee related liabilities, including with respect to recently acquired companies, drove the majority of this change. |
• | Net earnings for the first half of 2015 increased $9 million and included an increase of $36 million of depreciation and amortization expense as compared to the comparable period of 2014. Amortization expense primarily relates to the amortization of intangible assets acquired in connection with acquisitions and increased due to the impact of recently acquired businesses. Depreciation expense relates to both the Company's manufacturing and operating facilities as well as instrumentation leased to customers under operating-type lease arrangements and increased due primarily to increases in assets leased to customers and the impact of recently acquired businesses. Depreciation and amortization are non-cash expenses that decrease earnings without a corresponding impact to operating cash flows. |
• | €500 million aggregate principal amount of floating rate senior notes due 2017 (the “2017 Euronotes”). The 2017 Euronotes were issued at 100% of their principal amount, will mature on June 30, 2017 and bear interest at a floating rate equal to three-month EURIBOR plus 0.45% per year. |
• | €600 million aggregate principal amount of 1.0% senior notes due 2019 (the “2019 Euronotes”). The 2019 Euronotes were issued at 99.696% of their principal amount, will mature on July 8, 2019 and bear interest at the rate of 1.0% per year. |
• | €800 million aggregate principal amount of 1.7% senior notes due 2022 (the “2022 Euronotes”). The 2022 Euronotes were issued at 99.651% of their principal amount, will mature on January 4, 2022 and bear interest at the rate of 1.7% per year. |
• | €800 million aggregate principal amount of 2.5% senior notes due 2025 (the “2025 Euronotes”). The 2025 Euronotes were issued at 99.878% of their principal amount, will mature on July 8, 2025 and bear interest at the rate of 2.5% per year. |
• | on the floating rate 2017 Euronotes quarterly in arrears on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2015; |
• | on the 2019 Euronotes and 2025 Euronotes annually in arrears on July 8 of each year, commencing on July 8, 2016; and |
• | on the 2022 Euronotes annually in arrears on January 4 of each year, commencing on January 4, 2016. |
• | Pall could under-perform relative to our expectations and the price that we pay for it, or not perform in accordance with our anticipated timetable. |
• | Pall could cause our financial results to differ from our own or the investment community’s expectations in any given period, or over the long-term. |
• | Earnings charges relating to the acquisition of Pall could adversely impact our operating results in any given period, and the impact may be substantially different from period to period. |
• | The integration of Pall could create demands on our management, operational resources and financial and internal control systems that we are unable to effectively manage. |
• | We could experience difficulty in integrating Pall’s personnel, operations and financial and other systems and retaining key employees and customers. |
• | We may be unable to achieve the cost savings or other synergies that we anticipate realizing as a result of the acquisition of Pall. |
• | By acquiring Pall we may assume unknown liabilities or internal control deficiencies, and the liabilities that we assume as a result of the acquisition may prove greater than anticipated. Any of these liabilities or deficiencies may increase our expenses, adversely affect our financial position or cause us to fail to meet our public financial reporting obligations. |
• | As a result of the acquisition of Pall, we expect to record significant goodwill and other indefinite lived intangible assets on our balance sheet. If we are not able to realize the value of these assets, we may be required to incur charges relating to the impairment of these assets. |
(a) | Exhibits: |
2.1 | Agreement and Plan of Merger, dated as of May 12, 2015, by and among Danaher Corporation, Pentagon Merger Sub, Inc. and Pall Corporation (incorporated by reference from Exhibit 2.1 to Danaher Corporation's Current Report on Form 8-K filed on May 13, 2015 (Commission File Number: 1-8089)) + | |
3.1 | Restated Certificate of Incorporation of Danaher Corporation (incorporated by reference from Exhibit 3.1 to Danaher Corporation's Quarterly Report on Form 10-Q for the quarter ended June 29, 2012 (Commission File Number: 1-8089)) | |
3.2 | Amended and Restated By-laws of Danaher Corporation (incorporated by reference from Exhibit 3.2 to Danaher Corporation's Annual Report on Form 10-K for the year ended December 31, 2011 (Commission File Number: 1-8089)) | |
4.1 | Indenture dated as of July 8, 2015, by and between Danaher Corporation, as guarantor, DH Europe Finance S.A., as issuer, and The Bank of New York Mellon Trust Company, N.A. as trustee (“Danaher International Indenture”) (incorporated by reference from Exhibit 4.1 to Danaher Corporation's Current Report on Form 8-K filed on July 8, 2015 (Commission File Number: 1-8089)) | |
4.2 | First Supplemental Indenture to Danaher International Indenture, dated as of July 8, 2015, by and between Danaher Corporation, as guarantor, DH Europe Finance S.A., as issuer, and The Bank of New York Mellon Trust Company, N.A. as trustee relating to the Floating Rate Senior Notes due 2017, the 1.000% Senior Notes due 2019, the 1.700% Senior Notes due 2022 and the 2.500% Senior Notes due 2025 (incorporated by reference from Exhibit 4.2 to Danaher Corporation's Current Report on Form 8-K filed on July 8, 2015 (Commission File Number: 1-8089)) | |
4.3 | Paying and Calculation Agency Agreement, dated as of July 8, 2015, by and among Danaher International, Danaher Corporation, and The Bank of New York Mellon, London Branch, as paying and calculation agent (incorporated by reference from Exhibit 4.3 to Danaher Corporation's Current Report on Form 8-K filed on July 8, 2015 (Commission File Number: 1-8089)) | |
4.4 | Form of Floating Rate Senior Notes due 2017 (included in Exhibit 4.2) | |
4.5 | Form of 1.000% Senior Notes due 2019 (included in Exhibit 4.2) | |
4.6 | Form of 1.700% Senior Notes due 2022 (included in Exhibit 4.2) | |
4.7 | Form of 2.500% Senior Notes due 2025 (included in Exhibit 4.2) | |
10.1 | Danaher Corporation 2007 Stock Incentive Plan, as amended * (incorporated by reference from Exhibit 10.1 to Danaher Corporation’s Current Report on Form 8-K filed on May 11, 2015 (Commission File Number: 1-8089)) | |
10.2 | Form of Danaher Corporation 2007 Stock Incentive Plan Stock Option Agreement for Non-Employee Directors * | |
10.3 | Form of Danaher Corporation 2007 Stock Incentive Plan RSU Agreement for Non-Employee Directors * | |
10.4 | Form of Danaher Corporation 2007 Stock Incentive Plan Stock Option Agreement * | |
10.5 | Form of Danaher Corporation 2007 Stock Incentive Plan RSU Agreement * | |
10.6 | Form of Danaher Corporation 2007 Stock Incentive Plan Performance Stock Unit Agreement * | |
10.7 | Credit Agreement, dated as of July 10, 2015, among Danaher Corporation, Bank of America, N.A., as Administrative Agent and a Swing Line lender, Citibank, N.A. as Syndication Agent, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets Inc., The Bank Of Tokyo - Mitsubishi UFJ, Ltd., BNP Paribas Securities Corp., US Bank National Association, HSBC Securities (USA) Inc. and Wells Fargo Securities, LLC as Joint Lead Arrangers and Joint Book Managers, and the other lenders referred to therein (incorporated by reference from Exhibit 4.1 to Danaher Corporation’s Current Report on Form 8-K filed on July 10, 2015 (Commission File Number: 1-8089)) | |
10.8 | Credit Agreement, dated as of July 10, 2015, among Danaher Corporation, Citibank, N.A. as Administrative Agent, Bank of America, N.A., as Syndication Agent, Deutsche Bank Securities Corp. and Barclays Bank Plc, as Documentation Agents, Citigroup Global Markets Inc., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Deutsche Bank Securities Corp. and Barclays Bank Plc, as Joint Lead Arrangers and Joint Bookrunners and the other lenders referred to therein (incorporated by reference from Exhibit 4.2 to Danaher Corporation’s Current Report on Form 8-K filed on July 10, 2015 (Commission File Number: 1-8089)) | |
11.1 | Computation of per-share earnings (See Note 11, “Net Earnings Per Share”, to our Consolidated Condensed Financial Statements). | |
12.1 | Calculation of ratio of earnings to fixed charges | |
31.1 | Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1 | Certification of Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
32.2 | Certification of Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
101.INS | XBRL Instance Document ** | |
101.SCH | XBRL Taxonomy Extension Schema Document ** | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document ** | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document ** | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document ** | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document ** |
+ | The schedules to the Agreement and Plan of Merger have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. Danaher will furnish copies of such schedules to the Securities and Exchange Commission upon request. |
* | Indicates management contract or compensatory plan, contract or arrangement. |
** | Attached as Exhibit 101 to this report are the following documents formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Condensed Balance Sheets as of July 3, 2015 and December 31, 2014, (ii) Consolidated Condensed Statements of Earnings for the three and six months ended July 3, 2015 and June 27, 2014, (iii) Consolidated Condensed Statements of Comprehensive Income for the three and six months ended July 3, 2015 and June 27, 2014, (iv) Consolidated Condensed Statement of Stockholders’ Equity for the six months ended July 3, 2015, (v) Consolidated Condensed Statements of Cash Flows for the six months ended July 3, 2015 and June 27, 2014, and (vi) Notes to Consolidated Condensed Financial Statements. |
DANAHER CORPORATION: | ||||
Date: | July 22, 2015 | By: | /s/ Daniel L. Comas | |
Daniel L. Comas | ||||
Executive Vice President and Chief Financial Officer | ||||
Date: | July 22, 2015 | By: | /s/ Robert S. Lutz | |
Robert S. Lutz | ||||
Senior Vice President and Chief Accounting Officer |
I. | NOTICE OF STOCK OPTION GRANT |
Date of Grant: | |
Exercise Price per Share | $ |
Total Number of Shares Granted | |
Type of Option | Nonstatutory Stock Option |
Expiration Date | Tenth anniversary of Date of Grant |
Vesting Schedule: | 100% vested upon grant |
II. | AGREEMENT |
OPTIONEE | DANAHER CORPORATION | |
Signature | Signature | |
Print Name | Print Name | |
Title | ||
Residence Address | ||
I. | NOTICE OF GRANT |
Date of Grant: | |
Number of Restricted Stock Units | |
Vesting Schedule: | |
Vesting Conditions: | The time-based vesting criteria will be satisfied with respect to 100% of the shares underlying the RSUs on the earlier of (1) the first anniversary of the Date of Grant, or (2) the date of, and immediately prior to, the next annual meeting of shareholders of the Company following the Date of Grant. |
II. | AGREEMENT |
PARTICIPANT | DANAHER CORPORATION | |
Signature | Signature | |
Print Name | Print Name | |
Title | ||
Residence Address | ||
I. | NOTICE OF STOCK OPTION GRANT |
Date of Grant: | |
Exercise Price per Share | $ |
Total Number of Shares Granted | |
Type of Option | Nonstatutory Stock Option |
Expiration Date | Tenth anniversary of Date of Grant |
Vesting Schedule: | |
Time-Based Vesting Criteria | The time-based vesting criteria will be satisfied with respect to ____% of the Options on each of the _____________ anniversaries of the Date of Grant. |
II. | AGREEMENT |
OPTIONEE | DANAHER CORPORATION | |
Signature | Signature | |
Print Name | Print Name | |
Title | ||
Residence Address | ||
(i) | the Agreement, including this Appendix, which together with the Plan sets forth the terms and conditions of participation in the Plan; |
(ii) | a copy of the Company’s most recent annual return (i.e., Form 10-K) and most recent financial reports; and |
(iii) | a copy of the Plan and a description of the Plan (the “Description”) (i.e., the Company’s Form S-8 Plan Prospectus under the U.S. Securities Act of 1933, as amended); the Company will |
1.Purposes for processing of the Personal Data | 1. Цели обработки Персональных данных | ||
1.1. | Granting to the Optionee restricted share units or rights to purchase shares of common stock. | 1.1. | Предоставление Субъектам персональных данных ограниченных прав на акции (RSU) или прав покупки обыкновенных акций. |
1.2. | Compliance with the effective Russian Federation laws; | 1.2. | Соблюдение действующего законодательства Российской Федерации; |
2.The Optionee hereby grants consent to processing of the personal data listed below | 2. Субъект персональных данных настоящим дает согласие на обработку перечисленных ниже персональных данных | ||
2.1. | Last name, first name, patronymic, year, month, date and place of birth, gender, age, address, citizenship, information on education, contact details (home address(es), direct office, home and mobile telephone numbers, e-mail address, etc.), photographs; | 2.1. | Фамилия, имя, отчество, год, месяц, дата и место рождения, пол, возраст, адрес, гражданство, сведения об образовании, контактная информация (домашний(е) адрес(а), номера прямого офисного, домашнего и мобильного телефонов, адрес электронной почты и др.), фотографии; |
2.2. | Information contained in personal identification documents (including passport details), tax identification number and number of the State Pension Insurance Certificate, including photocopies of passports, visas, work permits, drivers licenses, other personal documents; | 2.2. | Сведения, содержащиеся в документах, удостоверяющих личность, в том числе паспортные данные, ИНН и номер страхового свидетельства государственного пенсионного страхования, в том числе фотокопии паспортов, виз, разрешений на работу, водительских удостоверений, других личных документов; |
2.3. | Information on employment, including the list of duties, information on the current and former employers, information on promotions, disciplinary sanctions, transfer to other position / work, etc.; | 2.3. | Информация о трудовой деятельности, включая должностные обязанности, информация о текущем и прежних работодателях, сведения о повышениях, дисциплинарных взысканиях, переводах на другую должность/работу, и т.д.; |
2.4. | Information on the Optionee’s salary amount, information on salary changes, on participation in employer benefit plans and programs, on bonuses paid, etc.; | 2.4. | Информация о размере заработной платы Субъекта персональных данных, данные об изменении заработной платы, об участии в премиальных системах и программах Работодателя, информация о выплаченных премиях, и т.д.; |
2.5. | Information on work time, including hours scheduled for work per week and hours actually worked; | 2.5. | Сведения о рабочем времени, включая нормальную продолжительность рабочего времени в неделю и количество фактически отработанного рабочего времени; |
2.6. | Information on potential membership of certain categories of employees having rights for guarantees and benefits in accordance with the Russian Federation Labor Code and other effective legislation; | 2.6. | Сведения о принадлежности к определенным категориям работников, которым предоставляются гарантии и льготы в соответствии с Трудовым кодексом Российской Федерации и иным действующим законодательством; |
2.7. | Information on the Optionee’s tax status (exempt, tax resident status, etc.); | 2.7. | Информация о налоговом статусе Субъекта персональных данных (освобождение от уплаты налогов, является ли налоговым резидентом и т.д.); |
2.8. | Information on shares of Common Stock or directorships held by the Optionee, details of all awards or any other entitlement to shares of Common Stock awarded, cancelled, exercised, vested, unvested or outstanding; | 2.8. | Информация об обыкновенных акциях или членстве в совете директоров Субъекта персональных данных, обо всех программах вознаграждения или иных правах на получение обыкновенных акций, которые были предоставлены, аннулированы, исполнены, погашены, непогашены или подлежат выплате. |
2.9. | Any other information, which may become necessary to the Company in connection with the purposes specified in Clause 3 above. | 2.9. | Любые иные данные, которые могут потребоваться Операторам в связи с осуществлением целей, указанных в п. 3 выше. |
the “Personal Data” | далее - «Персональные данные» | ||
3.1.The Optionee hereby consents to performing the following operations with the Personal Data: | 3.1. Субъект персональных данных настоящим дает согласие на совершение с Персональными данными перечисленных ниже действий: |
3.1.1 | processing of the Personal Data, including collection, systematization, accumulation, storage, verification (renewal, modification), use, dissemination (including transfer), impersonalizing, blockage, destruction; | 3.1.1. | обработка Персональных данных, включая сбор, систематизацию, накопление, хранение, уточнение (обновление, изменение), использование, распространение (в том числе передача), обезличивание, блокирование, уничтожение персональных данных; |
3.1.2 | transborder transfer of the Personal Data to îperators located on the territory of foreign states. The Optionee hereby confirms that he was notified of the fact that the recipients of the Personal Data may be located in foreign states that do not ensure adequate protection of rights of personal data subjects; | 3.1.2. | трансграничная передача Персональных данных операторам на территории любых иностранных государств. Субъект персональных данных настоящим подтверждает, что он был уведомлен о том, что получатели Персональных данных могут находиться в иностранных государствах, не обеспечивающих адекватной защиты прав субъектов персональных данных; |
3.1.3 | including Personal Data into generally accessible sources of personal data (including directories, address books and other), placing Personal Data on the Company’s web-sites on the Internet. | 3.1.3. | включение Персональных данных в общедоступные источники персональных данных (в том числе справочники, адресные книги и т.п.), размещение Персональных данных на сайтах Операторов в сети Интернет. |
3.2.General description of the data processing methods used by the Company | 3.2. Общее описание используемых Оператором(ами) способов обработки персональных данных | ||
3.2.1.When processing the Personal Data, the Company undertakes the necessary organizational and technical measures for protecting the Personal Data from unlawful or accidental access to them, from destruction, change, blockage, copying, dissemination of Personal Data, as well as from other unlawful actions. | 3.2.1. При обработке Персональных данных Операторы принимают необходимые организационные и технические меры для защиты Персональных данных от неправомерного или случайного доступа к ним, уничтожения, изменения, блокирования, копирования, распространения Персональных данных, а также от иных неправомерных действий. | ||
3.2.2.Processing of the Personal Data by the Company shall be performed using the data processing methods that ensure confidentiality of the Personal Data, except where: (1) Personal Data is impersonalized; and (2) in relation to publicly available Personal Data; and in compliance with the established requirements to ensuring the security of personal data, the requirements to the tangible media of biometric personal data and to the technologies for storage of such data outside personal data information systems in accordance with the effective legislation. | 3.2.2. Обработка Персональных данных Операторами осуществляется при помощи способов, обеспечивающих конфиденциальность таких данных, за исключением следующих случаев: (1) в случае обезличивания Персональных данных; (2) в отношении общедоступных Персональных данных; и при соблюдении установленных требований к обеспечению безопасности персональных данных, требований к материальным носителям биометрических персональных данных и технологиям хранения таких данных вне информационных систем персональных данных в соответствии с действующим законодательством. | ||
4.Term, revocation procedure | 4. Срок, порядок отзыва | ||
This Statement of Consent is valid for an indefinite term. The Optionee may revoke this consent by sending to Company a written notice at least ninety (90) days in advance of the proposed consent revocation date. The Optionee agrees that during the specified notice period the Company is not obliged to cease processing of personal data or to destroy the personal data of the Optionee. | Настоящее согласие действует в течение неопределенного срока. Субъект персональных данных может отозвать настоящее согласие путем направления Оператору(ам) письменного(ых) уведомления(ий) не менее чем за 90 (девяносто) дней до предполагаемой даты отзыва настоящего согласия. Субъект персональных данных соглашается на то, что в течение указанного срока Оператор(ы) не обязан(ы) прекращать обработку персональных данных и уничтожать персональные данные Субъекта персональных данных. | ||
I. | NOTICE OF GRANT |
Date of Grant: | |
Number of Restricted Stock Units | |
Vesting Schedule: | |
Vesting Conditions: | The time-based vesting criteria will be satisfied with respect to [_________]% of the shares underlying the RSUs on each of the [_________] anniversaries of the Date of Grant. |
Performance Objective | Set forth on Addendum A (if applicable) |
II. | AGREEMENT |
PARTICIPANT | DANAHER CORPORATION | |
Signature | Signature | |
Print Name | Print Name | |
Title | ||
Residence Address | ||
1.Purposes for processing of the Personal Data | 1. Цели обработки Персональных данных | ||
1.1. | Granting to the Participant restricted share units or rights to purchase shares of common stock. | 1.1. | Предоставление Субъектам персональных данных ограниченных прав на акции (RSU) или прав покупки обыкновенных акций. |
1.2. | Compliance with the effective Russian Federation laws; | 1.2. | Соблюдение действующего законодательства Российской Федерации; |
2.The Participant hereby grants consent to processing of the personal data listed below | 2. Субъект персональных данных настоящим дает согласие на обработку перечисленных ниже персональных данных | ||
2.1. | Last name, first name, patronymic, year, month, date and place of birth, gender, age, address, citizenship, information on education, contact details (home address(es), direct office, home and mobile telephone numbers, e-mail address, etc.), photographs; | 2.1. | Фамилия, имя, отчество, год, месяц, дата Фамилия, имя, отчество, год, месяц, дата гражданство, сведения об образовании, контактная информация (домашний(е) адрес(а), номера прямого офисного, домашнего и мобильного телефонов, адрес электронной почты и др.), фотографии; |
2.2. | Information contained in personal identification documents (including passport details), tax identification number and number of the State Pension Insurance Certificate, including photocopies of passports, visas, work permits, drivers licenses, other personal documents; | 2.2. | Сведения, содержащиеся в документах, удостоверяющих личность, в том числе паспортные данные, ИНН и номер страхового свидетельства государственного пенсионного страхования, в том числе фотокопии паспортов, виз, разрешений на работу, водительских удостоверений, других личных документов; |
2.3. | Information on employment, including the list of duties, information on the current and former employers, information on promotions, disciplinary sanctions, transfer to other position / work, etc.; | 2.3. | Информация о трудовой деятельности, включая должностные обязанности, информация о текущем и прежних работодателях, сведения о повышениях, дисциплинарных взысканиях, переводах на другую должность/работу, и т.д.; |
2.4. | Information on the Participant’s salary amount, information on salary changes, on participation in employer benefit plans and programs, on bonuses paid, etc.; | 2.4. | Информация о размере заработной платы Субъекта персональных данных, данные об изменении заработной платы, об участии в премиальных системах и программах Работодателя, информация о выплаченных премиях, и т.д.; |
2.5. | Information on work time, including hours scheduled for work per week and hours actually worked; | 2.5. | Сведения о рабочем времени, включая нормальную продолжительность рабочего времени в неделю и количество фактически отработанного рабочего времени; |
2.6. | Information on potential membership of certain categories of employees having rights for guarantees and benefits in accordance with the Russian Federation Labor Code and other effective legislation; | 2.6. | Сведения о принадлежности к определенным категориям работников, которым предоставляются гарантии и льготы в соответствии с Трудовым кодексом Российской Федерации и иным действующим законодательством; |
2.7. | Information on the Participant’s tax status (exempt, tax resident status, etc.); | 2.7. | Информация о налоговом статусе Субъекта персональных данных (освобождение от уплаты налогов, является ли налоговым резидентом и т.д.); |
2.8. | Information on shares of Common Stock or directorships held by the Participant, details of all awards or any other entitlement to shares of Common Stock awarded, cancelled, exercised, vested, unvested or outstanding; | 2.8. | Информация об обыкновенных акциях или членстве в совете директоров Субъекта персональных данных, обо всех программах вознаграждения или иных правах на получение обыкновенных акций, которые были предоставлены, аннулированы, исполнены, погашены, непогашены или подлежат выплате. |
2.9. | Any other information, which may become necessary to the Company in connection with the purposes specified in Clause 3 above. | 2.9. | Любые иные данные, которые могут потребоваться Операторам в связи с осуществлением целей, указанных в п. 3 выше. |
the “Personal Data” | далее – «Персональные данные» | ||
3.1.The Participant hereby consents to performing the following operations with the Personal Data: | 3.1.Субъект персональных данных настоящим дает согласие на совершение с Персональными данными перечисленных ниже действий: | ||
3.1.1. | processing of the Personal Data, including collection, systematization, accumulation, storage, verification (renewal, modification), use, dissemination (including transfer), impersonalizing, blockage, destruction; | 3.1.1. | обработка Персональных данных, включая сбор, систематизацию, накопление, хранение, уточнение (обновление, изменение), использование, распространение (в том числе передача), обезличивание, блокирование, уничтожение персональных данных; |
3.1.2. | transborder transfer of the Personal Data to îperators located on the territory of foreign states. The Participant hereby confirms that he was notified of the fact that the recipients of the Personal Data may be located in foreign states that do not ensure adequate protection of rights of personal data subjects; | 3.1.2. | трансграничная передача Персональных данных операторам на территории любых иностранных государств. Субъект персональных данных настоящим подтверждает, что он был уведомлен о том, что получатели Персональных данных могут находиться в иностранных государствах, не обеспечивающих адекватной защиты прав субъектов персональных данных; |
3.1.3. | including Personal Data into generally accessible sources of personal data (including directories, address books and other), placing Personal Data on the Company's web-sites on the Internet. | 3.1.3. | включение Персональных данных в общедоступные источники персональных данных (в том числе справочники, адресные книги и т.п.), размещение Персональных данных на сайтах Операторов в сети Интернет. |
3.2.General description of the data processing methods used by the Company | 3.2.Общее описание используемых Оператором(ами) способов обработки персональных данных | ||
3.2.1.When processing the Personal Data, the Company undertakes the necessary organizational and technical measures for protecting the Personal Data from unlawful or accidental access to them, from destruction, change, blockage, copying, dissemination of Personal Data, as well as from other unlawful actions. | 3.2.1. При обработке Персональных данных Операторы принимают необходимые организационные и технические меры для защиты Персональных данных от неправомерного или случайного доступа к ним, уничтожения, изменения, блокирования, копирования, распространения Персональных данных, а также от иных неправомерных действий. |
3.2.2.Processing of the Personal Data by the Company shall be performed using the data processing methods that ensure confidentiality of the Personal Data, except where: (1) Personal Data is impersonalized; and (2) in relation to publicly available Personal Data; and in compliance with the established requirements to ensuring the security of personal data, the requirements to the tangible media of biometric personal data and to the technologies for storage of such data outside personal data information systems in accordance with the effective legislation. | 3.2.2. Обработка Персональных данных Операторами осуществляется при помощи способов, обеспечивающих конфиденциальность таких данных, за исключением следующих случаев: (1) в случае обезличивания Персональных данных; (2) в отношении общедоступных Персональных данных; и при соблюдении установленных требований к обеспечению безопасности персональных данных, требований к материальным носителям биометрических персональных данных и технологиям хранения таких данных вне информационных систем персональных данных в соответствии с действующим законодательством. | ||
4.Term, revocation procedure | 4. Срок, порядок отзыва | ||
This Statement of Consent is valid for an indefinite term. The Participant may revoke this consent by sending to Company a written notice at least ninety (90) days in advance of the proposed consent revocation date. The Participant agrees that during the specified notice period the Company is not obliged to cease processing of Personal Data or destroy the Personal Data of the Participant. | Настоящее согласие действует в течение неопределенного срока. Субъект персональных данных может отозвать настоящее согласие путем направления Оператору(ам) письменного(ых) уведомления(ий) не менее чем за 90 (девяносто) дней до предполагаемой даты отзыва настоящего согласия. Субъект персональных данных соглашается на то, что в течение указанного срока Оператор(ы) не обязан(ы) прекращать обработку персональных данных и уничтожать персональные данные Субъекта персональных данных. | ||
I. | NOTICE OF GRANT |
Date of Grant: | |
Target PSUs: | |
Performance Period: | |
Vesting Conditions: | Per this Agreement (including Addendum A) |
II. | AGREEMENT |
PARTICIPANT | DANAHER CORPORATION | |
Signature | Signature | |
Print Name | Print Name | |
Title | ||
Residence Address | ||
TSR Percentile Rank | Percentage of Target PSUs That Will Vest on Vesting Date |
75th percentile and above | 200% |
55th percentile | 100% |
35th percentile | 50% |
Below 35th percentile | 0% |
(a) | if the Company’s TSR for the Performance Period is positive, in no event shall less than twenty-five percent (25%) of the Target PSUs vest; and |
(b) | if the Company’s TSR for the Performance Period is negative, in no event shall more than one hundred percent (100%) of the Target PSUs vest. |
• | “Beginning Price” means, with respect to the Company and any other Comparison Group member, the average of the closing market prices of such company’s common stock on the principal exchange on which such stock is traded for the twenty (20) consecutive trading days ending with the last trading day before the beginning of the Performance Period. For the purpose of determining Beginning Price, the value of dividends and other distributions shall be determined by treating them as reinvested in additional shares of stock at the closing market price on the ex-dividend date. |
• | “Comparison Group” means the Company and each other company included in the Standard & Poor’s 500 index on the first day of the Performance Period and, except as provided below, the common stock (or similar equity security) of which is continually listed or traded on a national securities exchange from the first day of the Performance Period through the last trading day of the Performance Period. In the event a member of the Comparison Group files for bankruptcy or liquidates due to an insolvency, such company shall continue to be treated as a Comparison Group member, and such company’s Ending Price will be treated as $0 if the common stock (or |
• | “Ending Price” means, with respect to the Company and any other Comparison Group member, the average of the closing market prices of such company’s common stock on the principal exchange on which such stock is traded for the twenty (20) consecutive trading days ending on the last trading day of the Performance Period. For the purpose of determining Ending Price, the value of dividends and other distributions shall be determined by treating them as reinvested in additional shares of stock at the closing market price on the ex-dividend date. |
• | “Performance Period” means the Performance Period specified in the Notice of Grant. |
• | “Target PSUs” means the target number of PSUs subject to the Award as specified in the Notice of Grant. |
• | “TSR” shall be determined with respect to the Company and any other Comparison Group member by dividing: (a) the sum of (i) the difference obtained by subtracting the applicable Beginning Price from the applicable Ending Price plus (ii) all dividends and other distributions on the respective shares with an ex-dividend date that falls during the Performance Period by (b) the applicable Beginning Price. Any non-cash distributions shall be valued at fair market value. For the purpose of determining TSR, the value of dividends and other distributions shall be determined by treating them as reinvested in additional shares of stock at the closing market price on the date of distribution. |
• | “TSR Percentile Rank” means the percentile ranking of the Company’s TSR among the TSRs for the Comparison Group members for the Performance Period. TSR Percentile Rank is determined by ordering the Comparison Group members (plus the Company if the Company is not one of the |
TSR Percentile Rank = | (N - R) | * 100 |
N |
Exhibit 12.1 | |||||||||||||||||||||||
Danaher Corporation | |||||||||||||||||||||||
Statement Regarding Computation of Ratio of Earnings to Fixed Charges | |||||||||||||||||||||||
(In millions, except ratio data) | |||||||||||||||||||||||
Year Ended December 31 | Six Months Ended | ||||||||||||||||||||||
2010 | 2011 | 2012 | 2013 | 2014 | July 3, 2015 | ||||||||||||||||||
Fixed Charges: | |||||||||||||||||||||||
Gross Interest Expense | $ | 117.1 | $ | 141.6 | $ | 157.5 | $ | 145.9 | $ | 122.7 | $ | 60.0 | |||||||||||
Interest Element of Rental Expense | 15.2 | 19.9 | 22.3 | 19.4 | 18.8 | 10.4 | |||||||||||||||||
Interest on Unrecognized Tax Benefits | — | — | — | — | — | — | |||||||||||||||||
Total Fixed Charges | $ | 132.3 | $ | 161.5 | $ | 179.8 | $ | 165.3 | $ | 141.5 | $ | 70.4 | |||||||||||
Earnings Available for Fixed Charges: | |||||||||||||||||||||||
Earnings (Excluding Earnings from Equity Investees) Before Income Taxes Plus Distributed Income of Equity Investees | $ | 1,915.8 | $ | 2,429.4 | $ | 2,985.4 | $ | 3,566.0 | $ | 3,481.8 | $ | 1,649.9 | |||||||||||
Add Fixed Charges | 132.3 | 161.5 | 179.8 | 165.3 | 141.5 | 70.4 | |||||||||||||||||
Interest on Unrecognized Tax Benefits | — | — | — | — | — | — | |||||||||||||||||
Total Earnings Available for Fixed Charges | $ | 2,048.1 | $ | 2,590.9 | $ | 3,165.2 | $ | 3,731.3 | $ | 3,623.3 | $ | 1,720.3 | |||||||||||
Ratio of Earnings to Fixed Charges | 15.5 | 16.0 | 17.6 | 22.6 | 25.6 | 24.4 | |||||||||||||||||
NOTE: These ratios include Danaher Corporation and its consolidated subsidiaries. The ratio of earnings to fixed charges was computed by dividing earnings by fixed charges for the periods indicated, where “earnings” consist of (1) earnings (excluding earnings from equity investees) before income taxes plus distributed income of equity investees; plus (2) fixed charges, and “fixed charges” consist of (A) interest, whether expensed or capitalized, on all indebtedness, (B) amortization of premiums, discounts and capitalized expenses related to indebtedness, and (C) an interest component representing the estimated portion of rental expense that management believes is attributable to interest. Interest on unrecognized tax benefits is included in the tax provision in the Company's Consolidated Condensed Statements of Earnings and is excluded from the computation of fixed charges. | |||||||||||||||||||||||
1. | I have reviewed this Quarterly Report on Form 10-Q of Danaher Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: | July 22, 2015 | By: | /s/ Thomas P. Joyce, Jr. | |
Name: | Thomas P. Joyce, Jr. | |||
Title: | President and Chief Executive Officer |
1. | I have reviewed this Quarterly Report on Form 10-Q of Danaher Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: | July 22, 2015 | By: | /s/ Daniel L. Comas | |
Name: | Daniel L. Comas | |||
Title: | Executive Vice President and Chief Financial Officer |
Date: | July 22, 2015 | By: | /s/ Thomas P. Joyce, Jr. |
Name: | Thomas P. Joyce, Jr. | ||
Title: | President and Chief Executive Officer |
Date: | July 22, 2015 | By: | /s/ Daniel L. Comas |
Name: | Daniel L. Comas | ||
Title: | Executive Vice President and Chief Financial Officer |
Goodwill (Goodwill By Segment) (Details) - USD ($) $ in Millions |
Jul. 03, 2015 |
Dec. 31, 2014 |
---|---|---|
Goodwill [Line Items] | ||
Total goodwill | $ 16,935.1 | $ 16,964.2 |
Test & Measurement | ||
Goodwill [Line Items] | ||
Total goodwill | 3,203.7 | 3,238.4 |
Environmental | ||
Goodwill [Line Items] | ||
Total goodwill | 1,953.4 | 1,937.3 |
Life Sciences & Diagnostics | ||
Goodwill [Line Items] | ||
Total goodwill | 6,394.1 | 6,345.2 |
Dental | ||
Goodwill [Line Items] | ||
Total goodwill | 3,127.3 | 3,142.9 |
Industrial Technologies | ||
Goodwill [Line Items] | ||
Total goodwill | $ 2,256.6 | $ 2,300.4 |
Contingencies (Warranty Accrual) (Details) $ in Millions |
6 Months Ended |
---|---|
Jul. 03, 2015
USD ($)
| |
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward] | |
Balance, December 31, 2014 | $ 139.1 |
Accruals for warranties issued during the period | 58.2 |
Settlements made | (65.7) |
Additions due to acquisitions | 0.8 |
Effect of foreign currency translation | (2.0) |
Balance, July 3, 2015 | $ 130.4 |
2X^.8`UDQ@*';%BQGX#S$T#QF>:ZSM!`OI5.=\SPI_SZ)3%[F+G:O$Z_IX5CK"7\Q
M\WO>+LU%4:6R<$JQG[O?\'2#0PUI$+]2<:D&[XY._DW*=SWXL9N[2.<@,K&M
M=8A$/3[$4F29CJ24_W1!;YJ:.'R_1E\WRU7IOR656,KL=[JKCRI;Y#H[L4_.
M6?TJ+]]%MX9`!]S*K&K^.MMS53B(,B9CW\&B"WL14>378O/MD+-K%)HPYR6&CY@9
MP8+Z7(*OE3CS_^A\G;Y==;A=T+=C]?UA76"W*K!;".RF%N^_M+B&>?A2A"W.
M5(-MTM-QI,3>^/'PYNS\.A]YNI-/>)%WHH%?PC;2.')!'VXVW4V-Z"%8R>[V
ME+3A_\R!@MK'Y7U8V_%)C8''[O9!YE]:_`-02P,$%`````@`.3#W1F^/J=RP
M`0``%@0``!D```!X;"]W;W)K